As described above (Figure 2), sample #30 was originally classified as a heterogenous HER2-enriched tumor, however, the derived organoid model displayed no HER2 amplification and indeed showed resistance to HER2 inhibition (Figure S7). The gene discussed is ERBB2; the disease is neoplasm.